Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Ferdeghini

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 1, 2008
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposalMaria Vittoria Davì, Lisa Bodei, Marco Ferdeghini, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 2019
A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult HypoglycemiaMarco Dauriz, Chiara Maneschi, Claudia Castelli, et al.
The Journal of Clinical Endocrinology and Metabolism|June 11, 2009
Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawalAnna Frigo, Angela Dardano, Elisa Danese, et al.
European Journal of Endocrinology|February 21, 2015
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangementsChiara Colato, Caterina Vicentini, Silvia Cantara, et al.
Nuclear Medicine Communications|February 1, 2007
Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawalAngela Vaiano, A Claudio Traino, Giuseppe Boni, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2012
Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?Cosimo Durante, Teresa Montesano, Marco Attard, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 19, 2004
In vivo and in vitro detection of dopamine d2 receptors in uveal melanomasLisa Bodei, Leo J Hofland, Diego Ferone, et al.
International Journal of Cardiology|April 29, 2019
Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic stenosisRoberto Scarsini, Rosaria Cantone, Gabriele Venturi, et al.
Endocrine-Related Cancer|July 13, 2016
RET mutation and increased angiogenesis in medullary thyroid carcinomasAntonella Verrienti, Giovanni Tallini, Chiara Colato, et al.
The Journal of Clinical Endocrinology and Metabolism|July 28, 2010
Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomasCosimo Durante, Marco Attard, Massimo Torlontano, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 1, 2008
Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposalMaria Vittoria Davì, Lisa Bodei, Marco Ferdeghini, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 2019
A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult HypoglycemiaMarco Dauriz, Chiara Maneschi, Claudia Castelli, et al.
The Journal of Clinical Endocrinology and Metabolism|June 11, 2009
Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawalAnna Frigo, Angela Dardano, Elisa Danese, et al.
European Journal of Endocrinology|February 21, 2015
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangementsChiara Colato, Caterina Vicentini, Silvia Cantara, et al.
Nuclear Medicine Communications|February 1, 2007
Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawalAngela Vaiano, A Claudio Traino, Giuseppe Boni, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2012
Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?Cosimo Durante, Teresa Montesano, Marco Attard, et al.
Cancer Biotherapy & Radiopharmaceuticals|February 19, 2004
In vivo and in vitro detection of dopamine d2 receptors in uveal melanomasLisa Bodei, Leo J Hofland, Diego Ferone, et al.
International Journal of Cardiology|April 29, 2019
Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic stenosisRoberto Scarsini, Rosaria Cantone, Gabriele Venturi, et al.
Endocrine-Related Cancer|July 13, 2016
RET mutation and increased angiogenesis in medullary thyroid carcinomasAntonella Verrienti, Giovanni Tallini, Chiara Colato, et al.
The Journal of Clinical Endocrinology and Metabolism|July 28, 2010
Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomasCosimo Durante, Marco Attard, Massimo Torlontano, et al.
Pageof 3